These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 6883961

  • 1. Conversion from intravenous aminophylline to sustained-release theophylline: computer simulation versus in vivo results.
    Hatton RC, Gotz VP, Robinson JD, Russell WL, Ryerson GG.
    Clin Pharm; 1983; 2(4):347-52. PubMed ID: 6883961
    [Abstract] [Full Text] [Related]

  • 2. The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
    Yamazaki M, Fukutomi O, Kondo N, Kato Z, Nakashima Y, Shinoda S, Agata H, Kondo T, Imaeda N, Orii T.
    Int J Clin Pharmacol Ther; 1994 Nov; 32(11):625-31. PubMed ID: 7874380
    [Abstract] [Full Text] [Related]

  • 3. The use of parenteral aminophylline in patients taking slow release theophylline preparations: an observation of clinical practice.
    Arbab OA, Wiggins J, Ayres JG, Stableforth DE.
    Br J Dis Chest; 1985 Apr; 79(2):161-71. PubMed ID: 3986120
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
    Valet SB, Schwartz RH, Brooks JG.
    Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
    [Abstract] [Full Text] [Related]

  • 7. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
    Takagi K, Hasegawa T, Ogura Y, Yamaki K, Suzuki R, Satake T, Imaeda N, Mizukami Y.
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum theophylline concentrations and pulmonary function tests after administration of two sustained-release formulations containing theophylline in patients affected by chronic obstructive lung disease.
    Fontana G, Cresci F, Lo Sapio P, Panuccio P.
    Int J Clin Pharmacol Res; 1987 Oct; 7(5):351-6. PubMed ID: 3667008
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reliability of theophylline clearance in determining chronic oral dosage regimens.
    Slotfeldt ML, Johnson CE, Grambau G, Weg JG.
    Am J Hosp Pharm; 1979 Jan; 36(1):66-8. PubMed ID: 758787
    [Abstract] [Full Text] [Related]

  • 13. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D, Molz KH, Staib AH, Rietbrock N.
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the Chiou method for determining theophylline dosages.
    Johnson MH, Burkle WS.
    Clin Pharm; 1984 May; 3(2):174-8. PubMed ID: 6723223
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rapid estimation of total body clearance of theophylline in patients receiving intravenous aminophylline infusion.
    Lau AH, O'Connor T, Lam G, Lui CY, Al-Bazzaz FJ, Chiou WL.
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):12-5. PubMed ID: 3957483
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.